Ten-day versus 14-day levofloxacin-containing triple therapy for second-line anti- Helicobacter pylori eradication in Taiwan

Gastroenterology Research and Practice

Volumn 2013, Issue , 2013, Pages

  Tai, Wei Chen ^a   Chiu, Chien Hua ^b   Liang, Chih Ming ^a   Chang, Kuo Chin ^a   Kuo, Chung Mou ^a   Chiu, Yi Chun ^a   Wu, Keng Liang ^a   Hu, Ming Luen ^a   Chou, Yeh Pin ^a   Chiou, Shue Shian ^a   Chiu, King Wah ^a   Kuo, Chung Huang ^a   Hu, Tsung Hui ^a   Lin, Ming Tsung ^a   Chuah, Seng Kee ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ESOMEPRAZOLE; LEVOFLOXACIN;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ERADICATION THERAPY; FEMALE; FOLLOW UP; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NONHUMAN; RASH; RETROSPECTIVE STUDY; TAIWAN; TREATMENT DURATION; TREATMENT RESPONSE; UREA BREATH TEST;

EID: 84887498456     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2013/932478     Document Type: Article

References (36)

1. Graham D. Y., Lew G. M., Klein P. D., Evans D. G., Evans D. J. Jr., Saeed Z. A., Malaty H. M., Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Annals of Internal Medicine 1992 116 9 705 708 2-s2.0-0027070575 (Pubitemid 23033112)
2. Chuah S. K., Tsay F. W., Hsu P. I., Wu D. C., A new look at anti- Helicobacter pylori therapy. World Journal of Gastroenterology 2011 17 35 3971 3975 2-s2.0-80054851399 10.3748/wjg.v17.i35.3971
3. Kuo C. H., Hsu P. I., Kuo F. C., Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial. Journal of Antimicrobial Chemotherapy 2013 68 222 228
4. Hsu P. I., Wu D. C., Wu J. Y., Graham D. Y., Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter 2011 16 2 146 152 2-s2.0-79952716248 10.1111/j.1523-5378.2011. 00829.x
5. Graham D. Y., Fischbach L., Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010 59 8 1143 1153 2-s2.0-77954704743 10.1136/gut.2009.192757
6. Graham D. Y., Lu H., Yamaoka Y., A report card to grade Helicobacter pylori therapy. Helicobacter 2007 12 4 275 278 2-s2.0-34547585030 10.1111/j.1523-5378.2007.00518.x (Pubitemid 47196342)
7. Yamaoka Y., Graham D. Y., Lu H., Should triple therapy for Helicobacter pylori infection be abandoned as no longer effective? The American Journal of Gastroenterology 2008 4 65 67
8. Malfertheiner P., Megraud F., O'Morain C. A., Atherton J., Axon A. T. R., Bazzoli F., Gensini G. F., Gisbert J. P., Graham D. Y., Rokkas T., El-Omar E. M., Kuipers E. J., Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report. Gut 2012 61 5 646 664 2-s2.0-84859589351 10.1136/gutjnl-2012-302084
9. Hu T. H., Chuah S. K., Hsu P. I., Wu D.-C., Tai W.-C., Chiu Y.-C., Wu K.-L., Kuo C.-M., Hu M.-L., Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori. The American Journal of the Medical Sciences 2011 342 3 177 181 2-s2.0-80052259224 10.1097/MAJ.0b013e31821fc2aa
10. Hsu P. I., Wu D. C., Wu J. Y., Graham D. Y., Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 Days. Helicobacter 2011 16 2 139 145 2-s2.0-79952713160 10.1111/j.1523-5378.2011.00828.x
11. Kuo C. H., Hu H. M., Kuo F. C., Hsu P. I., Chen A., Yu F.-J., Tsai P.-Y., Wu I.-C., Wang S.-W., Li C.-J., Weng B.-C., Chang L.-L., Jan C.-M., Wang W.-M., Wu D.-C., Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. Journal of Antimicrobial Chemotherapy 2009 63 5 1017 1024 2-s2.0-64649086513 10.1093/jac/dkp034
12. Fock K. M., Katelaris P., Sugano K., Ang T. L., Hunt R., Talley N. J., Lam S. K., Xiao S.-D., Tan H. J., Wu C.-Y., Jung H. C., Hoang B. H., Kachintorn U., Goh K.-L., Chiba T., Rani A. A., Second Asia-Pacific Conference. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. Journal of Gastroenterology and Hepatology 2009 24 10 1587 1600 2-s2.0-68749089263 10.1111/j.1440-1746.2009.05982.x
13. Gisbert J. P., De La Morena F., Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Alimentary Pharmacology and Therapeutics 2006 23 1 35 44 2-s2.0-33644925601 10.1111/j.1365-2036.2006.02737.x (Pubitemid 43381164)
14. Cheng H. C., Chang W. L., Chen W. Y., Yang H. B., Wu J. J., Sheu B. S., Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy. Helicobacter 2007 12 4 359 363 2-s2.0-34547594433 10.1111/j.1523-5378.2007.00507.x (Pubitemid 47196332)
15. Chuah S. K., Hsu P. I., Chang K. C., Chiu Y.-C., Wu K.-L., Chou Y.-P., Hu M.-L., Tai W.-C., Chiu K.-W., Chiou S.-S., Wu D.-C., Hu T.-H., Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori. Helicobacter 2012 17 3 216 223 2-s2.0-84860154494 10.1111/j.1523-5378.2012.00937.x
16. Yakoob J., Abid S., Jafri W., Abbas Z., Islam M., Ahmad Z., Comparison of biopsy-based methods for the detection of Helicobacter pylori infection. British Journal of Biomedical Science 2006 63 4 159 162 2-s2.0-33845933302 (Pubitemid 46033475)
17. Peng N. J., Lai K. H., Liu R. S., Lee S.-C., Tsay D.-G., Lo C.-C., Tseng H.-H., Huang W.-K., Lo G.-H., Hsu P.-I., Clinical significance of oral urease in diagnosis of H. pylori infection by 13C-urea breath test. Digestive Diseases and Sciences 2001 46 8 1772 1778 2-s2.0-0034898225 10.1023/A:1010626225949 (Pubitemid 32727112)
18. Bilardi C., Dulbecco P., Zentilin P., Reglioni S., Iiritano E., Parodi A., Accornero L., Savarino E., Mansi C., Mamone M., Vigneri S., Savarino V., A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clinical Gastroenterology and Hepatology 2004 2 11 997 1002 2-s2.0-9144258031 10.1016/S1542-3565(04)00458-6 (Pubitemid 39539749)
19. Schrauwen R. W., Janssen M. J., de Boer W. A., Seven-day PPI-triple therapy with levofloxacin is very effective for Helicobacter pylori eradication. The Netherlands Journal of Medicine 2009 67 3 96 101 2-s2.0-63049084214
20. di Caro S., Franceschi F., Mariani A., Thompson F., Raimondo D., Masci E., Testoni A., La Rocca E., Gasbarrini A., Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. Digestive and Liver Disease 2009 41 7 480 485 2-s2.0-67349145247 10.1016/j.dld.2008.09.013
21. Gisbert J. P., Pérez-Aisa A., Bermejo F., Second-line therapy with levofloxacin after failure of treatment to eradicate Helicobacter pylori infection: time trends in a Spanish multicenter study of 1000 patients. Journal of Clinical Gastroenterology 2013 47 130 135
22. Hsu P. I., Lai K. H., Tseng H. H., Lo G.-H., Lo C.-C., Lin C.-K., Cheng J.-S., Chan H.-H., Ku M.-K., Peng N.-J., Chien E.-J., Chen W., Hsu P.-N., Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. Alimentary Pharmacology and Therapeutics 2001 15 2 195 201 2-s2.0-0035126453 10.1046/j.1365-2036.2001.00903.x (Pubitemid 32142496)
23. Yahav J., Shmuely H., Niv Y., Bechor J., Samra Z., In vitro activity of levofloxacin against Helicobacter pylori isolates from patients after treatment failure. Diagnostic Microbiology and Infectious Disease 2006 55 1 81 83 2-s2.0-33646469364 10.1016/j.diagmicrobio.2005.12.003
24. Antos D., Schneider-Brachert W., Bästlein E., Hänel C., Haferland C., Buchner M., Meier E., Trump F., Stolte M., Lehn N., Bayerdörffer E., 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter 2006 11 1 39 45 2-s2.0-33645296575 10.1111/j.0083-8703.2006.00375.x
25. Gisbert J. P., "Rescue" regimens after Helicobacter pylori treatment failure. World Journal of Gastroenterology 2008 14 35 5385 5402 2-s2.0-64849083887 10.3748/wjg.14.5385
26. Tanaka M., Isogai E., Isogai H., Hayashi S., Hirose K., Kimura K., Sugiyama T., Sato K., Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori. Journal of Antimicrobial Chemotherapy 2002 49 6 1039 1040 2-s2.0-0035992160 (Pubitemid 34692903)
27. Guslandi M., Review article: alternative antibacterial agents for Helicobacter pylori eradication. Alimentary Pharmacology and Therapeutics 2001 15 10 1543 1547 2-s2.0-0034789301 10.1046/j.1365-2036.2001.01064.x (Pubitemid 32912396)
28. Matsumoto Y., Miki I., Aoyama N., Shirasaka D., Watanabe Y., Morita Y., Toyoda M., Mitani T., Miyachi H., Tamura T., Kasuga M., Levofloxacin-versus metronidazole-based rescue therapy for H. pylori infection in Japan. Digestive and Liver Disease 2005 37 11 821 825 2-s2.0-33644873329 10.1016/j.dld.2005.06. 002 (Pubitemid 44356109)
29. Coelho L. G., Moretzsohn L. D., Vieira W. L., Gallo M. A., Passos M. C. F., Cindr J. M., Cerqueira M. C., Vitiello L., Ribeiro M. L., Mendonça S., Pedrazzoli-Júnior J., Castro L. P., New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study. Alimentary Pharmacology and Therapeutics 2005 21 6 783 787 2-s2.0-20144387230 10.1111/j.1365-2036.2005.02370.x (Pubitemid 40469006)
30. Marzio L., Coraggio D., Capodicasa S., Grossi L., Cappello G., Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter 2006 11 4 237 242 2-s2.0-33745922076 10.1111/j.1523-5378.2006. 00407.x (Pubitemid 44051349)
31. Wong W. M., Gu Q., Chu K. M., Yee Y. K., Fung F. M. Y., Tong T. S. M., Chan A. O. O., Lai K. C., Chan C. K., Wong B. C. Y., Lansoprazole, levofloxacin and amoxicillin triple therapy versus quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics 2006 23 3 421 427 2-s2.0-33644929196 10.1111/j.1365-2036.2006. 02764.x (Pubitemid 43382022)
32. Kim J. M., Kim J. S., Kim N., Kim S. G., Jung H. C., Song I. S., Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. International Journal of Antimicrobial Agents 2006 28 1 6 13 2-s2.0-33745215810 10.1016/j.ijantimicag.2006.02.015
33. Tai W. C., Hu T. H., Lee C. H., Chen H.-H., Huang C. C., Chuah S.-K., Ano-perianal tuberculosis: 15 years of clinical experiences in Southern Taiwan. Colorectal Disease 2010 12 7 e114 e120 2-s2.0-84855418044
34. Liou J. M., Chen C. C., Chen M. J., Chang C.-Y., Fang Y.-J., Lee J.-Y., Sheng W.-H., Wang H.-P., Wu M.-S., Lin J.-T., Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial. Journal of Antimicrobial Chemotherapy 2011 66 8 1847 1852 2-s2.0-79960458098 10.1093/jac/dkr217
35. Miehlke S., Krasz S., Schneider-Brachert W., Kuhlisch E., Berning M., Madisch A., Laass M. W., Neumeyer M., Jebens C., Zekorn C., Knoth H., Vieth M., Stolte M., Lehn N., Morgner A., Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter 2011 16 6 420 426 2-s2.0-79961241897 10.1111/j.1523-5378.2011.00867.x
36. Chuah S. K., Tai W. C., Hsu P. I., The efficacy of second-line anti- Helicobacter pylori therapy using an extended 14-days levofloxacin/amoxicillin/ protonpumpinhibitors-a pilot study. Helicobacter 2012 17 374 381